Insight Molecular Diagnostics Inc. annual report, FY2022

Business context and reporting period

The supplied filing is Oncocyte Corporation’s Form 10-K for the fiscal year ended December 31, 2022, filed April 12, 2023. This differs from the request metadata naming Insight Molecular Diagnostics Inc.; the filing identifies Oncocyte Corporation (Nasdaq: OCX). Figures below are in U.S. dollars; financial statement amounts are generally in millions unless stated otherwise.

Oncocyte develops molecular diagnostic tests and provides pharmaceutical services. At year-end, DetermaRx was its only commercialized clinical test; DetermaIO, VitaGraft and DetermaCNI remained in development or early-access/research use. The company subsequently sold 70% of Razor Genomics, which held DetermaRx, and transferred the related assets and liabilities in February 2023, retaining approximately 30% of Razor.

Financial results and liquidity

Research and development expense rose to $7.3 million from $5.0 million; sales and marketing expense rose to $1.1 million from $0.6 million; general and administrative expense was $21.9 million versus $22.3 million. The company recorded $10.0 million in stock-based compensation. Reported operating results also included a $31.0 million noncash gain from the change in fair value of contingent consideration, an $18.7 million goodwill impairment, and a $25.9 million impairment of Razor assets held for sale. The contingent-consideration gain reduced reported continuing-operations loss, while the Razor impairment was included in discontinued operations.

At December 31, 2022, total liabilities were $60.5 million, including $45.7 million of contingent consideration liabilities and lease liabilities; no loans payable remained on the balance sheet. The company also had $5.3 million of redeemable convertible preferred stock, carrying a 6% cumulative dividend and a cash redemption date of April 8, 2024, subject to specified earlier triggers. Restricted cash was $1.7 million. Equity was $34.3 million.

Management stated it expected available resources to fund operations for at least 12 months after issuance of the financial statements, while also warning that continuing losses would require additional financing unless revenue grows. Subsequent to year-end, the company reported approximately $13.9 million in gross proceeds from an April 2023 common-stock offering; it used about $1.1 million to redeem part of its preferred stock. This financing is a subsequent event, not year-end cash.

Material changes and notable events

• Revenue declined 27% overall, and continuing-operations revenue declined 56%. DetermaRx revenue was reported in discontinued operations after the planned Razor divestiture.
• Operating cash use increased by $9.6 million. Year-end cash and cash equivalents fell by $13.0 million from 2021.
• In August and December 2022, the company reduced headcount, including a December reduction affecting more than 40% of full-time employees; it recorded $1.9 million of related severance and benefits costs for 2022. The December reduction was completed in February 2023.
• In February 2023, Oncocyte completed the Razor transaction without monetary consideration for the 70% equity transfer, apart from $115,660 for specified equipment. Management said the divestiture would eliminate DetermaRx development and commercialization costs.
• On February 7, 2023, Oncocyte terminated its co-development agreement with Life Technologies. In February it also amended Chronix acquisition earnout terms, eliminating milestone payments and revising certain revenue-sharing obligations.
• Oncocyte transferred its listing from Nasdaq Global Market to Nasdaq Capital Market in February 2023 and received an additional 180-day period to regain the $1.00 minimum bid-price requirement.

Outlook, risks and contingencies

Management expected continued net losses and significant development costs, with operating expenses managed in light of available cash. It gave no specific revenue, earnings or test-launch guidance. Commercial prospects depend on clinical evidence, physician adoption, regulatory requirements and Medicare or private-payer coverage and reimbursement. The filing notes that DetermaIO and VitaGraft were not yet broadly commercialized and that payer coverage and collection timing remained uncertain.

Key risks include the need for further capital and potential shareholder dilution; dependence on a small number of tests and Pharma Services customers; regulatory uncertainty for laboratory-developed tests; clinical-development and technology-transfer risks; payer reimbursement and collection delays; competition and intellectual-property challenges; and potential data-security, privacy and laboratory-compliance issues. Three Pharma Services customers represented 43%, 14% and 11% of 2022 consolidated revenue, respectively.

The company disclosed a material weakness in internal control over financial reporting involving insufficient accounting resources and inadequate controls over complex, unusual or non-routine transactions. Management described remediation efforts, but the filing’s controls discussion also says disclosure controls and procedures were effective, while the internal-control assessment concludes they were not effective at a reasonable-assurance level. The independent auditor issued an unqualified opinion on the financial statements but was not engaged to audit internal control over financial reporting.

Important facts for investors to verify

• Confirm the issuer identity: the filing is Oncocyte Corporation’s 2022 Form 10-K, not a filing under the company name in the request metadata.
• Track post-filing cash, burn rate and financing needs; reconcile management’s 12-month runway statement with subsequent financing, preferred-stock redemption obligations and ongoing losses.
• Review the status and economics of the Razor/DetermaRx divestiture, including the retained 30% interest and any remaining obligations.
• Verify progress toward reimbursement, clinical validation and commercialization for DetermaIO, VitaGraft and DetermaCNI, and the effects of terminating the Life Technologies agreement.
• Assess remediation of the disclosed material weakness and clarify the apparent inconsistency in the filing’s discussion of control effectiveness.
• Monitor Nasdaq minimum-bid-price compliance, dilution from securities outstanding or future issuance, and the preferred stock’s redemption and dividend terms.